Up a level |
de Knegt, Gerjo J, Dickinson, Laura ORCID: 0000-0001-5557-9396, Pertinez, Henry, Evangelopoulos, Dimitrios, McHugh, Timothy D, Bakker-Woudenberg, Irma AJM, Davies, Gerry R ORCID: 0000-0002-3819-490X and de Steenwinkel, Jurriaan EM
(2017)
Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model.
TUBERCULOSIS, 105.
pp. 113-118.
De Francesco, Davide, Wang, Xinzhu, Dickinson, Laura ORCID: 0000-0001-5557-9396, Underwood, Jonathan, Bagkeris, Emmanouil, Babalis, Daphne S, Mallon, Patrick WG, Post, Frank A, Vera, Jaime H, Sachikonye, Memory et al (show 5 more authors)
(2021)
Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV.
PLOS ONE, 16 (7).
e0253861-.
Fox, Julie, Tiraboschi, Juan M, Herrera, Carolina ORCID: 0000-0003-3701-752X, Else, Laura, Egan, Deirdre, Dickinson, Laura ORCID: 0000-0001-5557-9396, Jackson, Akil ORCID: 0000-0002-4574-544X, Olejniczak, Natalia, Back, David, Khoo, Saye ORCID: 0000-0002-2769-0967 et al (show 2 more authors)
(2016)
Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
Journal of acquired immune deficiency syndromes (1999), 73 (3).
pp. 252-257.
Dickinson, Laura ORCID: 0000-0001-5557-9396, Amin, Janaki, Else, Laura, Boffito, Marta, Egan, Deirdre, Owen, Andrew ORCID: 0000-0002-9819-7651, Khoo, Saye ORCID: 0000-0002-2769-0967, Back, David, Orrell, Catherine, Clarke, Amanda et al (show 6 more authors)
(2016)
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.
CLINICAL PHARMACOKINETICS, 55 (7).
pp. 861-873.
Duwal, Sulav, Dickinson, Laura ORCID: 0000-0001-5557-9396, Khoo, Saye ORCID: 0000-0002-2769-0967 and von Kleist, Max
(2018)
Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes.
PLOS COMPUTATIONAL BIOLOGY, 14 (6).
e1006155-.
Gini, Joshua, Olagunju, Adeniyi ORCID: 0000-0002-6588-5749, Dickinson, Laura ORCID: 0000-0001-5557-9396, Waitt, Catriona ORCID: 0000-0003-0134-5855, Neary, Megan ORCID: 0000-0002-4960-2139, Else, Laura J, Siccardi, Marco ORCID: 0000-0002-3539-7867 and Khoo, Saye ORCID: 0000-0002-2769-0967
(2019)
Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics.
PHARMACOGENOMICS, 20 (4).
pp. 217-224.
Dickinson, Laura ORCID: 0000-0001-5557-9396, Walimbwa, Stephen, Singh, Yashna, Kaboggoza, Julian, Kintu, Kenneth, Sihlangu, Mary, Coombs, Julie-Anne, Malaba, Thokozile R, Byamugisha, Josaphat, Pertinez, Henry et al (show 11 more authors)
(2021)
Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1.
CLINICAL INFECTIOUS DISEASES, 73 (5).
E1200-E1207.
Gurjar, Rohan, Dickinson, Laura ORCID: 0000-0001-5557-9396, Carr, Daniel, Stohr, Wolfgang, Bonora, Stefano, Owen, Andrew ORCID: 0000-0002-9819-7651, D'Avolio, Antonio, Cursley, Adam, De Castro, Nathalie, Fatkenheuer, Gerd et al (show 6 more authors)
(2022)
Influence of <i>UGT1A1</i> and <i>SLC22A6</i> polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study.
PHARMACOGENOMICS JOURNAL, 23 (1).
pp. 14-20.
Duwal, Sulav, Dickinson, Laura ORCID: 0000-0001-5557-9396, Khoo, Saye ORCID: 0000-0002-2769-0967 and von Kleist, Max
(2019)
Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis.
PLoS computational biology, 15 (1).
e1006740-e1006740.
Dickinson, Laura, Amin, J, Else, Laura, Boffito, M, Egan, Deirdre, Owen, Andrew ORCID: 0000-0002-9819-7651, Khoo, Saye ORCID: 0000-0002-2769-0967, Back, David, Orrell, C, Clarke, A et al (show 6 more authors)
(2015)
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Clinical pharmacology and therapeutics, 98 (4).
pp. 406-416.
Fox, Julie, Tiraboschi, Juan M, Herrera, Carolina, Else, Laura, Egan, Deirdre, Dickinson, Laura ORCID: 0000-0001-5557-9396, Jackson, Akil, Olejniczak, Natalia, Back, David, Khoo, Saye ORCID: 0000-0002-2769-0967 et al (show 2 more authors)
(2016)
Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 73 (3).
pp. 252-257.
Herrera, Carolina, Lwanga, Julianne, Lee, Ming, Mantori, Suna, Amara, Alieu ORCID: 0000-0002-1137-2948, Else, Laura, Penchala, Sujan Dilly, Egan, Deirdre, Challenger, Elizabeth ORCID: 0000-0002-8978-6067, Dickinson, Laura ORCID: 0000-0001-5557-9396 et al (show 4 more authors)
(2021)
Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP).
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76 (8).
pp. 2129-2136.
FitzGerald, Richard, Dickinson, Laura ORCID: 0000-0001-5557-9396, Else, Laura, Fletcher, Thomas, Hale, Colin, Amara, Alieu ORCID: 0000-0002-1137-2948, Walker, Lauren ORCID: 0000-0002-3827-4387, Penchala, Sujan Dilly, Lyon, Rebecca, Shaw, Victoria ORCID: 0000-0002-0429-0186 et al (show 9 more authors)
(2022)
Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
CLINICAL INFECTIOUS DISEASES, 75 (1).
E525-E528.
Wang, Xinzhu, Boffito, Marta, Dickinson, Laura ORCID: 0000-0001-5557-9396, Bagkeris, Emmanouil, Khoo, Saye ORCID: 0000-0002-2769-0967, Post, Frank A, Vera, Jaime, Williams, Ian, Ndoutoumou, Amalia, Anderson, Jane et al (show 5 more authors)
(2020)
Plasma NRTI concentration and their associations with liver and renal parameters in people living with HIV.
AIDS, 34 (5).
pp. 790-793.
Dickinson, Laura ORCID: 0000-0001-5557-9396, Yapa, H Manisha, Jackson, Akil ORCID: 0000-0002-4574-544X, Moyle, Graeme, Else, Laura, Amara, Alieu ORCID: 0000-0002-1137-2948, Khoo, Saye ORCID: 0000-0002-2769-0967, Back, David, Karolia, Zeenat, Higgs, Chris et al (show 1 more authors)
(2015)
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59 (10).
pp. 6080-6086.
Wang, Xinzhu, Boffito, Marta, Dickinson, Laura ORCID: 0000-0001-5557-9396, Bagkeris, Emmanouil, Khoo, Saye, Post, Frank A, Vera, Jaime, Williams, Ian, Ndoutoumou, Amalia, Anderson, Jane et al (show 5 more authors)
(2020)
Plasma nucleotide reverse transcriptase inhibitor concentration and their associations with liver and renal parameters in people living with HIV.
AIDS, 34 (5).
pp. 790-793.
Dickinson, Laura ORCID: 0000-0001-5557-9396, Bracchi, Margherita, Elliot, Emilie, Else, Laura, Khoo, Saye ORCID: 0000-0002-2769-0967, Back, David, Nelson, Mark and Boffito, Marta
(2016)
Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch.
.
Dickinson, Laura ORCID: 0000-0001-5557-9396, Gurjar, Rohan, Stoehr, Wolfgang, Bonora, Stefano, Owen, Andrew ORCID: 0000-0002-9819-7651, D'Avolio, Antonio, Cursley, Adam, Molina, Jean-Michel, Faeetkenheuer, Gerd, Vandekerckhove, Linos et al (show 5 more authors)
(2020)
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75 (3).
pp. 628-639.
Dickinson, Laura ORCID: 0000-0001-5557-9396, Winston, Alan, Boffito, Marta, Khoo, Saye ORCID: 0000-0002-2769-0967, Back, David and Siccardi, Marco ORCID: 0000-0002-3539-7867
(2016)
Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71 (4).
pp. 1041-1045.
Dickinson, Laura ORCID: 0000-0001-5557-9396, Jackson, Akil ORCID: 0000-0002-4574-544X, Garvey, L, Watson, Victoria, Khoo, Saye ORCID: 0000-0002-2769-0967, Boffito, M, Davies, Geraint ORCID: 0000-0002-3819-490X and Back, David
(2012)
Simultaneous population pharmacokinetic modelling of darunavir and ritonavir Once daily in HIV-infected patients: evaluation of lower ritonavir dose.
Journal of the International AIDS Society, 15 (4).
Duwal, Sulav, Seeler, Daniel, Dickinson, Laura ORCID: 0000-0001-5557-9396, Khoo, Saye ORCID: 0000-0002-2769-0967 and von Kleist, Max
(2019)
The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis.
FRONTIERS IN PHARMACOLOGY, 10.
199-.
Duwal, Sulav, Seeler, Daniel, Dickinson, Laura ORCID: 0000-0001-5557-9396, Khoo, Saye ORCID: 0000-0002-2769-0967 and von Kleist, Max
(2019)
The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis.
Frontiers in pharmacology, 10 (MAR).
p. 199.
Siccardi, Marco ORCID: 0000-0002-3539-7867, Dickinson, Laura ORCID: 0000-0001-5557-9396 and Owen, Andrew ORCID: 0000-0002-9819-7651
(2016)
Validation of Computational Approaches for Antiretroviral Dose Optimization (vol 60, pg 3838, 2016).
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61 (1).
e02367-e02316.
Olagunju, Adeniyi ORCID: 0000-0002-6588-5749, Anweh, Damien, Okafor, Ogechi, Dickinson, Laura ORCID: 0000-0001-5557-9396, Richman, Douglas ORCID: 0000-0003-0962-9254, Owen, Andrew ORCID: 0000-0002-9819-7651 and Adejuyigbe, Ebunoluwa ORCID: 0000-0002-8671-4965
(2019)
Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study.
Wellcome Open Research, 4.
p. 34.
Wootton, Daniel G ORCID: 0000-0002-5903-3881, Dickinson, Laura ORCID: 0000-0001-5557-9396, Pertinez, Henry, Court, Joanne, Eneje, Odiri, Keogan, Lynne, Macfarlane, Laura, Wilks, Sarah, Gallagher, Jane, Woodhead, Mark et al (show 2 more authors)
(2017)
A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days.
European Respiratory Journal, 49 (6).
1602170-.